Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Lung Neoplasms 3Stomach Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms, Male 2Uterine Neoplasms 1Thrombosis 1Peritoneal Neoplasms 1Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer 1Pancreatic Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1NSCLC 1Inflammatory Breast Neoplasms 1Infections 1Hypopharyngeal Neoplasms 1Hormone Refractory Prostate Cancer 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Drug-Related Side Effects and Adverse Reactions 1Carcinogenesis 1Breast Neoplasm Female 1Breast Diseases 1Amenorrhea 1Adenocarcinoma 1

Interventions

Prednisone 1PE regimen 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Hormone Refractory Prostate Cancer × Docetaxel × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡